Zobrazeno 1 - 10
of 164
pro vyhledávání: '"Noel Milpied"'
Autor:
Arnon, Nagler, Myriam, Labopin, Charles, Craddock, Gerard, Socié, Ibrahim, Yakoub-Agha, Tobias, Gedde-Dahl, Riitta, Niittyvuopio, Jennifer Louise, Byrne, Jan J, Cornelissen, Hélène, Labussière-Wallet, William, Arcese, Noel, Milpied, Jordi, Esteve, Jonathan, Canaani, Mohamad, Mohty
Publikováno v:
American journal of hematologyREFERENCES. 97(3)
FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutational status is a pivotal prognosticator in acute myeloid leukemia (AML) patients and significantly increases the risk of disease relapse. However, it remains unclear whether in F
Publikováno v:
Mycoses. 63:443-451
Invasive fungal infections (IFIs) contribute significantly to nosocomial illness in intensive care units (ICUs). Current practice guidelines recommend echinocandins, such as micafungin, for the treatment of invasive candidiasis. However, limited info
Autor:
Vincent Servant, Arnaud Pigneux, Yohann Bohbot, Nathan Mottal, Bernard Bégaud, Noel Milpied, Aude Berroneau, Emilien Bilion, Pierre Fenaux, Ghada Miremont-Salamé, Sophie Dimicoli-Salazar, Justine Perino, Hélène Théophile, Pierre Poustis, Aude Charbonnier, Kamel Laribi, Claire Calmettes
Publikováno v:
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, Wiley, In press, 86 (5), pp.991-998. ⟨10.1111/bcp.14211⟩
Br J Clin Pharmacol
British Journal of Clinical Pharmacology, Wiley, In press, 86 (5), pp.991-998. ⟨10.1111/bcp.14211⟩
Br J Clin Pharmacol
Aims Azacitidine (AZA), a pyrimidine analogue, is validated for high-risk myelodysplastic syndrome or low-blast acute myeloid leukaemia in unfit patients for more intensive treatment. This study assessed the putative link between cardiac failure (CF)
Autor:
Eliane Gluckman, Mahmoud Aljurf, Noel Milpied, Emanuele Angelucci, Fernanda Volt, Mauricette Michallet, Chantal Kenzey, Ibrahim Yakoub-Agha, Vanderson Rocha, Hiromi Hayashi, Gérard Michel, Eefke Petersen, Jaime Sanz, Jean-Hugues Dalle, Rachael Hough, Peter Bader, Annalisa Ruggeri, Nathalie Dhedin
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:2438-2446
Outcomes for adolescents and young adults (AYAs) with leukemia differ from other age groups and are still under-represented in clinical research. The aim of this study was to analyze outcomes of umbilical cord blood transplant (UCBT) in AYAs with acu
Autor:
Régis Peffault de Latour, Pierre-Simon Rohrlich, Anne Sirvent, Ana Berceanu, Matthieu Resche-Rigon, Charlotte Jubert, Didier Blaise, Bénédicte Neven, Marie-Thérèse Rubio, Patrice Chevallier, Stéphanie Nguyen, Jacques-Olivier Bay, Claude-Eric Bulabois, Noel Milpied, Mohamad Mohty, Gérard Socié, Pascal Turlure, Pedro Henrique Prata, Amandine Charbonnier
Publikováno v:
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, Elsevier, 2019, 25 (9), pp.1798-1802. ⟨10.1016/j.bbmt.2019.05.013⟩
Biology of Blood and Marrow Transplantation, 2019, 25 (9), pp.1798-1802. ⟨10.1016/j.bbmt.2019.05.013⟩
Biology of Blood and Marrow Transplantation, Elsevier, 2019, 25 (9), pp.1798-1802. ⟨10.1016/j.bbmt.2019.05.013⟩
Biology of Blood and Marrow Transplantation, 2019, 25 (9), pp.1798-1802. ⟨10.1016/j.bbmt.2019.05.013⟩
Prognosis of patients with graft failure is dismal, and retransplantation is the sole option for long-term survival. To address the interest of haploidentical transplantation as a salvage option in this context, we analyzed data from 24 patients with
Autor:
Jean Galtier, Noel Milpied, Françoix-Xavier Gros, Krimo Bouabdallah, Marie-Sarah Dilhuydy, Pauline Brice
Publikováno v:
The Lancet. Haematology. 8(9)
Autor:
Pierre‐Yves Dumas, Emilie Bérard, Claire Bréal, Stéphanie Dulucq, Delphine Réa, Franck Nicolini, Edouard Forcade, Melody Dufossée, Jean‐Max Pasquet, Béatrice Turcq, Audrey Bidet, Noel Milpied, Julie Déchanet‐Merville, Xavier Lafarge, Gabriel Etienne, François‐Xavier Mahon, French Intergroup in Chronic Myeloid Leukemia
Publikováno v:
Cancer Medicine
Cancer Medicine, Wiley, 2019, 8 (11), pp.4976-4985. ⟨10.1002/cam4.2371⟩
Cancer Medicine, 2019, 8 (11), pp.4976-4985. ⟨10.1002/cam4.2371⟩
Cancer Medicine, Vol 8, Iss 11, Pp 4976-4985 (2019)
Cancer Medicine, Wiley, 2019, 8 (11), pp.4976-4985. ⟨10.1002/cam4.2371⟩
Cancer Medicine, 2019, 8 (11), pp.4976-4985. ⟨10.1002/cam4.2371⟩
Cancer Medicine, Vol 8, Iss 11, Pp 4976-4985 (2019)
International audience; Natural Killer (NK) cells are innate lymphoid cells that can be cytotoxic toward a large panel of solid tumors and hematological malignancies including chronic myeloid leukemia (CML). Such a cytotoxicity depends on various rec
Autor:
Grzegorz W. Basak, Boris V. Afanasyev, Péter Reményi, Noel Milpied, Paolo Corradini, Madan Jagasia, Olaf Penack, Henrik Sengeloev, Frank Kroschinsky, Zinaida Peric, Ibrahim Yakoub-Agha, Rafael F. Duarte, Dietger Niederwieser, Edward Kanfer, Steffie van der Werf, Fabio Ciceri, Alessandro Rambaldi, Didier Blaise, Patrice Chevallier, Carlos Solano, Hildegard Greinix, Eric Beohou, Luca Castagna, Nicolaus Kröger, Hélène Schoemans, Agnieszka Tomaszewska, Christian Koenecke, Jean Bourhis, Benedetto Bruno, Christof Scheid, Marco Ladetto, Gérard Socié
Publikováno v:
Frontiers in Immunology
Tomaszewska, A, Jagasia, M, Beohou, E, van der Werf, S, Blaise, D, Kanfer, E, Milpied, N, Reményi, P, Ciceri, F, Bourhis, J H, Chevallier, P, Solano, C, Socié, G, Bruno, B, Rambaldi, A, Castagna, L, Kröger, N, Corradini, P, Afanasyev, B, Ladetto, M, Niederwieser, D, Scheid, C, Sengeloev, H, Kroschinsky, F, Yakoub-Agha, I, Schoemans, H, Koenecke, C, Penack, O, Perić, Z, Greinix, H, Duarte, R F & Basak, G W 2021, ' Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes : EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies ', Frontiers in Immunology, vol. 11, 613954 . https://doi.org/10.3389/fimmu.2020.613954
Frontiers in Immunology, Vol 11 (2021)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Tomaszewska, A, Jagasia, M, Beohou, E, van der Werf, S, Blaise, D, Kanfer, E, Milpied, N, Reményi, P, Ciceri, F, Bourhis, J H, Chevallier, P, Solano, C, Socié, G, Bruno, B, Rambaldi, A, Castagna, L, Kröger, N, Corradini, P, Afanasyev, B, Ladetto, M, Niederwieser, D, Scheid, C, Sengeloev, H, Kroschinsky, F, Yakoub-Agha, I, Schoemans, H, Koenecke, C, Penack, O, Perić, Z, Greinix, H, Duarte, R F & Basak, G W 2021, ' Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes : EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies ', Frontiers in Immunology, vol. 11, 613954 . https://doi.org/10.3389/fimmu.2020.613954
Frontiers in Immunology, Vol 11 (2021)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent gra
Autor:
Mauricette Michallet, Mathilde Hunault-Berger, Nicolaus Kröger, Jörg Cammenga, Johan Maertens, Monique C. Minnema, Jakob Passweg, Joan Hendrik Veelken, Riitta Niittyvuopio, Anja van Biezen, Stefan Schönland, Francisco José Márquez-Malaver, Simona Iacobelli, Arancha Bermúdez, Stéphanie Nguyen, Didier Blaise, Dietger Niederwieser, Ibrahim Yakoub-Agha, Noel Milpied, Patrick Hayden, Laurent Garderet, Yves Chalandon, Ellen Meijer, José Antonio Pérez-Simón, Jean Bourhis
Publikováno v:
Hayden, P J, Iacobelli, S, Pérez-Simón, J A, van Biezen, A, Minnema, M, Niittyvuopio, R, Schönland, S, Meijer, E, Blaise, D, Milpied, N, Márquez-Malaver, F J, Veelken, J H, Maertens, J, Michallet, M, Cammenga, J R, N'Guyen, S, Niederwieser, D, Hunault-Berger, M, Bourhis, J H, Passweg, J, Bermudez, A, Chalandon, Y, Yakoub-Agha, I, Garderet, L & Kröger, N 2020, ' Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP ', European Journal of Haematology, vol. 104, no. 3, pp. 181-189 . https://doi.org/10.1111/ejh.13352
European Journal of Haematology
European Journal of Haematology, 2020, 104 (3), pp.181-189. ⟨10.1111/ejh.13352⟩
Digital.CSIC. Repositorio Institucional del CSIC
instname
European Journal of Haematology, 104(3), 181-189. Wiley-Blackwell
European Journal of Haematology, 104(3), 181. Wiley-Blackwell
European Journal of Haematology, Vol. 104, No 3 (2020) pp. 181-189
European Journal of Haematology, Wiley, 2020, 104 (3), pp.181-189. ⟨10.1111/ejh.13352⟩
European Journal of Haematology. WILEY
European Journal of Haematology
European Journal of Haematology, 2020, 104 (3), pp.181-189. ⟨10.1111/ejh.13352⟩
Digital.CSIC. Repositorio Institucional del CSIC
instname
European Journal of Haematology, 104(3), 181-189. Wiley-Blackwell
European Journal of Haematology, 104(3), 181. Wiley-Blackwell
European Journal of Haematology, Vol. 104, No 3 (2020) pp. 181-189
European Journal of Haematology, Wiley, 2020, 104 (3), pp.181-189. ⟨10.1111/ejh.13352⟩
European Journal of Haematology. WILEY
[Objectives] The aim of this study was to compare the effect of the intensity of conditioning approaches used in allogeneic transplantation in myeloma—reduced intensity conditioning (RIC), non‐myeloablative (NMA), myeloablative conditioning (MAC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::465bcde0e81b55721a1f57e75c6e69cf
https://research.vumc.nl/en/publications/bcb5e8f0-4a5a-40fc-b72c-81940d8276fc
https://research.vumc.nl/en/publications/bcb5e8f0-4a5a-40fc-b72c-81940d8276fc
Autor:
Myriam Labopin, Philippe Moreau, Thierry Guillaume, Noel Milpied, Leonardo Magro, Pierre Peterlin, Florent Malard, Cécile Borel, Marie-Thérèse Rubio, Stephane Vigouroux, Patrice Chevallier, Reza Tabrizi, Mohamad Mohty, Ibrahim Yakoub-Agha, Alice Garnier, Béatrice Gaugler, Anne Huynh
Publikováno v:
Bone Marrow Transplantation
Bone Marrow Transplantation, Nature Publishing Group, 2019, 54 (11), pp.1815-1826. ⟨10.1038/s41409-019-0536-y⟩
Bone Marrow Transplantation, 2019, 54 (11), pp.1815-1826. ⟨10.1038/s41409-019-0536-y⟩
Bone Marrow Transplantation, Nature Publishing Group, 2019, 54 (11), pp.1815-1826. ⟨10.1038/s41409-019-0536-y⟩
Bone Marrow Transplantation, 2019, 54 (11), pp.1815-1826. ⟨10.1038/s41409-019-0536-y⟩
Thirty patients, with high-risk acute myeloid leukemia (AML, n = 20) or myelodysplastic syndrome (MDS, n = 10), were enrolled in a phase II trial entailing prophylactic post-transplant azacitidine (AZA) plus escalated doses of donor lymphocyte infusi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26f0a62aeab838595ec2506d495a9669
https://hal.univ-lorraine.fr/hal-02977226
https://hal.univ-lorraine.fr/hal-02977226